Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives



  • Nicola Cosentino Centro Cardiologico Monzino IRCCS, Milan, Italy. https://orcid.org/0000-0002-8628-3106
  • Jeness Campodonico Centro Cardiologico Monzino IRCCS, Milan, Italy. https://orcid.org/0000-0003-2276-9630
  • Valentina Milazzo Centro Cardiologico Monzino IRCCS, Milan, Italy. https://orcid.org/0000-0002-4864-0387
  • Katia Celentano Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • Marco Moltrasio Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • Pompilio Faggiano Cardiology Unit, Spedali Civili, University of Brescia, Italy.
  • Giancarlo Marenzi | giancarlo.marenzi@ccfm.it Centro Cardiologico Monzino IRCCS, Milan, Italy.


Patients with acute myocardial infarction (AMI) are at increased risk of recurrent ischemic events after hospital discharge, despite optimal medical therapy. Current practice guidelines strongly encourage the early assessment of the residual ischemic risk in post-AMI patients, in order to identify those who may benefit from a prolonged dual antiplatelet therapy. To this end, some scoring systems have been proposed. However, most scores were developed for patients with stable coronary artery disease undergoing percutaneous coronary intervention. Moreover, nearly all failed to be implemented in everyday clinical practice, probably because of the perceived complexity due to the large number of incorporated variables. Therefore, the identification of the ideal AMI patient who can benefit from a prolonged (beyond 1 year after the index event) dual antiplatelet therapy remains to be clarified, especially when the bleeding risk associated with such therapy is considered. In this review, we summarize the current evidence on the prolonged use of dual antiplatelet therapy after AMI, with a special focus on recent advances regarding the identification of high-risk patients who may derive a favorable net clinical benefit from such a therapeutic strategy.



PlumX Metrics


Download data is not yet available.


Cardiology - Reviews
Acute myocardial infarction, dual antiplatelet therapy, risk score, ischemic risk, bleeding
  • Abstract views: 879

  • PDF: 538
How to Cite
Cosentino, Nicola, Jeness Campodonico, Valentina Milazzo, Katia Celentano, Marco Moltrasio, Pompilio Faggiano, and Giancarlo Marenzi. 2019. “Extended Dual Antiplatelet Therapy After Acute Myocardial Infarction. Current Evidence and Future Perspectives”. Monaldi Archives for Chest Disease 89 (2). https://doi.org/10.4081/monaldi.2019.1046.

Most read articles by the same author(s)

1 2 3 4 > >>